Adverse events and follow-up
cancer, non-respiratory adverse, pain
ADVERSE EVENTS, CANCER, EVENT, VIRAL GASTROENTERITIS
Twenty patients (57%) experienced at least one (moderate or severe) acute exacerbation during the study in the UCG compared to 14 (47%) patients in the IG (p = 0.46). A total of 51 non-respiratory adverse events were reported during the study period, of which 20 (39%) occurred in the IG and 31 (61%) in the UCG. 47% of them led to a hospital admission. The adverse events were cardiovascular (25%), musculoskeletal (24%), internal (4%), cancer (2%) and other (45%). Two (swollen knee in UCG, joint pain in IG) were considered as “unlikely” related to the study, the other as “not” related to the study. One event (viral gastroenteritis) led to study discontinuation.After finishing 6 months of PR and 9 months after randomization, slightly more (65%) patients from the UCG continued supervised training (i.e. typically 1x/week in primary/community care) compared to the IG (42% p = 0.14).